MedTrace Logo

Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients

NCT03171636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2019-02-22

No results posted yet for this study

Summary

The assessment of the type and frequency of EGFR and KRAS mutations in lung cancer patients, as well as clinical-prognostic correlation, are crucial in the era of targeted therapies. EGFR-activating mutations predict responsiveness to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients and KRAS analysis will be useful in a near future for newest target drugs. In Brazil, few data about the prevalence of EGFR and KRAS mutations is available and their knowledge would allow optimize personalized medicine.

Conditions

  • Lung Neoplasms
  • KRAS Gene Mutation
  • EGFR Gene Mutation

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Hospital Erasto Gaertner

    lead OTHER

Principal Investigators

  • Thais A Almeida, MD · Liga Paranaense de Combate ao Cancer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-09-30
Completion
2019-01-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03171636 on ClinicalTrials.gov